|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| OPERATING ACTIVITIES: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization of fixed assets and intangibles | |||||
| Net accretion of time deposit premium, debt discount and debt issuance costs | |||||
| Provision for credit losses and unfunded commitments | |||||
| Accretion of loan discounts | |||||
| Stock-based compensation expense | |||||
| Deferred tax benefit | |||||
| Excess tax expense (benefit) from stock compensation | |||||
| Net amortization of premiums on debt securities | |||||
| Unrealized loss (gain) on equity securities recognized in earnings | |||||
| Change in cash surrender value and mortality rates of BOLI | |||||
| Net loss on sales of debt securities | |||||
| Change in fair value of government guaranteed loans using fair value option | |||||
| Gain on sales of mortgage LHFS | |||||
| Gain on sales of government guaranteed loans | |||||
| Originations of LHFS | |||||
| Proceeds from sales of LHFS | |||||
| Loss on sales of OREO | |||||
| Equity method investment loss (income) | |||||
| Servicing asset (recoveries) impairment, net | |||||
| Equity method investment loss | |||||
| Impairment on equity method investment | |||||
| Termination of derivatives designated as hedging instruments | |||||
| Gain on sale of premises and equipment | |||||
| Increase in other assets | |||||
| Increase in accounts payable and other liabilities | |||||
| Net cash provided by operating activities | |||||
| INVESTING ACTIVITIES: | |||||
| Net cash paid for acquisitions | |||||
| Purchases of AFS debt securities | |||||
| Proceeds from sales of AFS debt securities | |||||
| Proceeds from maturities, calls and pay downs of AFS debt securities | |||||
| Purchases of HTM debt securities | |||||
| Maturity, calls and paydowns on HTM debt securities | |||||
| Purchases of equity method securities | |||||
| Sales (purchases) of other investments | |||||
| Sales of securities under agreements to resell | |||||
| Proceeds from sales of equity securities | |||||
| Net loans originated | |||||
| Proceeds from sale of government guaranteed loans | |||||
| Proceeds from sales of premises and equipment | |||||
| Proceeds from sales of OREO and repossessed assets | |||||
| Net additions to premises and equipment | |||||
| Net cash used in investing activities | |||||
| FINANCING ACTIVITIES: | |||||
| Net increase in deposits | |||||
| Net increase (decrease) in advances from FHLB | |||||
| Proceeds from FHLB advances | |||||
| Repayments of FHLB advances | |||||
| Total net increase (decrease) in advances from FHLB | |||||
| Redemption of subordinated debt | |||||
| Proceeds from issuance of subordinated notes, net of debt issuance costs paid | |||||
| Net change in securities sold under agreement to repurchase | |||||
| Net proceeds on sale of common stock in public offering | |||||
| Proceeds from exercise of employee stock options | |||||
| Payments to tax authorities for stock-based compensation | |||||
| Proceeds from exercise of stock warrants | |||||
| Purchase of treasury stock | |||||
| Dividends paid | |||||
| Net cash provided by financing activities | |||||
| Net increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
Loading...